{"id":"W4322769118","doi":"10.1158/1538-7445.sabcs22-pd18-10","title":"Abstract PD18-10: Treatment of HER2-positive (HER2+) hormone-receptor positive (HR+) metastatic breast cancer (mBC) with the novel combination of zanidatamab, palbociclib, and fulvestrant","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Health Sciences Centre; Zymeworks (Canada); Sunnybrook Health Science Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Fulvestrant; Palbociclib; Metastatic breast cancer; Trastuzumab; Tolerability; Internal medicine; Oncology; Pertuzumab; Combination therapy; Breast cancer; Cancer; Adverse effect; Estrogen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004662214,0.0002874835,0.0005889045,0.0002642807,0.0001854015,0.0000286548,0.000185537,0.00007135646,0.0004576891],"category_scores_gemma":[0.00002336026,0.000181588,0.00009180218,0.001061643,0.001049682,0.0002080657,0.00006337805,0.0002927738,0.00001717863],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006294163,"about_ca_system_score_gemma":0.000689118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006143578,"about_ca_topic_score_gemma":0.0005115159,"domain_scores_codex":[0.9974635,0.0001287528,0.0003578895,0.0004930845,0.0009843169,0.0005724258],"domain_scores_gemma":[0.9976682,0.0005460591,0.0002142627,0.0004239031,0.0009611913,0.0001863873],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.01381926,0.001932346,0.003259636,0.0006652656,0.002729004,0.00007650125,0.01231109,0.0002954191,0.8516481,0.0005857411,0.001274101,0.1114035],"study_design_scores_gemma":[0.01237068,0.004731542,0.7710724,0.001257668,0.0004094649,0.00008285384,0.007077951,0.0001561796,0.2008909,0.000169161,0.001403615,0.0003776691],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850174,0.002992366,0.00007816651,0.007251275,0.00005268499,0.001589098,0.002770356,0.00004052952,0.000208098],"genre_scores_gemma":[0.9950116,0.0028779,0.0001681066,0.00004746026,0.0001071736,0.0006291476,0.0001562018,0.00006924324,0.0009331505],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7678127,"threshold_uncertainty_score":0.9287292,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05721189662845406,"score_gpt":0.3904071951522698,"score_spread":0.3331952985238158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}